tiprankstipranks
Advertisement
Advertisement
Roivant reports new clinical program for brepocitinib in lichen planopilaris
PremiumThe FlyRoivant reports new clinical program for brepocitinib in lichen planopilaris
1M ago
Bernstein bullish on Roivant Sciences, initiates with an Outperform
Premium
The Fly
Bernstein bullish on Roivant Sciences, initiates with an Outperform
1M ago
Roivant Sciences initiated with an Outperform at Bernstein
Premium
The Fly
Roivant Sciences initiated with an Outperform at Bernstein
2M ago
Unlocking Value from IP Settlement and Pipeline Catalysts: Why Roivant Deserves a Buy Rating
PremiumRatingsUnlocking Value from IP Settlement and Pipeline Catalysts: Why Roivant Deserves a Buy Rating
2M ago
Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement
Premium
The Fly
Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement
2M ago
Roivant Sciences price target raised to $29 from $26 at BofA
Premium
The Fly
Roivant Sciences price target raised to $29 from $26 at BofA
2M ago
Roivant’s Priovant Unit Gains FDA Priority Review for Brepocitinib
PremiumCompany AnnouncementsRoivant’s Priovant Unit Gains FDA Priority Review for Brepocitinib
2M ago
Roivant Sciences announces U.S. FDA accepted its NDA for brepocitinib
Premium
The Fly
Roivant Sciences announces U.S. FDA accepted its NDA for brepocitinib
2M ago
Roivant Sciences price target raised to $35 from $26 at Citi
Premium
The Fly
Roivant Sciences price target raised to $35 from $26 at Citi
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100